Image-01 (Image 01)
Levetiracetam Solution
Product Images NDC 63629-9615
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-9615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Label (Lbl636299615)
This is a medication containing 100mg of levetiracetam per 1mL. It must be dispensed in a container that is tightly closed and child-resistant. It should be stored between 15°C to 30°C, which is 59°F to 86°F. Patients should receive a Medication Guide with this medication, and it should be kept out of reach of children. The medication was produced by InvaTech Pharma Solutions and relabeled by Bryant Ranch Prepack, Inc.*
Image-02 (Levetiracetam Fig1)
This is a graph showing the responder rate with a 250% reduction from baseline in Study 1. There are percentages along the Y-axis ranging from 0% to 39.6%. There are two lines present, one labeled "Leviaseam 100" and the other "Leviaseam 000." The graph also notes that the results were statistically significant versus placebo.*
Image-01 (Levetiracetam Fig2)
The text displays a chart illustrating the responder rate in Study 2 during Period A, which shows the percentage reduction from baseline. The chart includes three treatment options: placebo, Levetiracetam at a dose of 1000 mg/day, and Levetiracetam at a dose of 2000 mg/day. The percentage of patients who responded to each treatment is displayed on the Y-axis, and the treatment options are displayed on the X-axis. A note in the text mentions that one of the treatment options showed a statistically significant difference compared to placebo.*
Image-03 (Levetiracetam Fig3)
This is a visual representation of the responder rate (those who experienced a >50% reduction from baseline) in the third clinical study. The graph shows the percentage of responders in each treatment group: placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The Levetiracetam group had a significantly higher responder rate compared to the placebo group.*
Image-04 (Levetiracetam Fig4)
This is a figure showing the responder rate in Study 4, which represents a 50% reduction from baseline. The percentages are displayed on a graph with two bars, one for placebo (N=97) and one for Levetiracetam (N=101). The percentage for Levetiracetam is 44.6%, while the percentage for placebo is 19.6%. The graph also includes a note that the result for Levetiracetam is statistically significant versus placebo.*
Image-05 (Levetiracetam Fig5)
The text describes a graph titled "Responder Rate for All Patients Ages 1 Month to < 4 Years (> 50% Reduction from Baseline) in Study 5". The graph displays percentages ranging from 0% to 45% for patients who are taking either a placebo or levetiracetam. The levetiracetam group shows a statistically significant reduction in responder rate compared to the placebo group.*
Image-06 (Levetiracetam Fig6)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
